Fluticasone furoate/fluticasone propionate - different drugs with different properties

Clinical Respiratory Journal

Volumn 5, Issue 3, 2011, Pages 183-184

  Biggadike, Keith ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; RELOVAIR; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG NOMENCLATURE; DRUG STRUCTURE; HUMAN; LETTER; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG PRESCRIPTIONS; HUMANS;

EID: 79959338251     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00244.x     Document Type: Letter

References (12)

1. Pearlman S. Research notes on Veramyst vs Flonase. Available at: (accessed 1 June 2011).
2. The Associated Press. Glaxo, Theravance report Relovair safety data. Available at: (accessed 1st June 2011).
3. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293: L660-7.
4. Biggadike K, Bledsoe RK, Hassall AM, Kirk BE, McLay IM, Shewchuk LM, Stewart EL. X-ray crystal structure of the novel enhanced affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008;51: 3349-52.
5. Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8: 54.
6. Baumann D, Bachert C, Hogger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39: 1540-50.
7. Allen A, Pierre LN, Rousell VM. Fluticasone furoate (FF) a novel inhaled corticosteroid demonstrates prolonged lung absorption kinetics in man. Am J Respir Crit Care Med. 2010;181: A5408.
8. van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, Lammers J-WJ. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy. 2010;65: 1531-5.
9. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25: 2021-41.
10. Gueron B, Demoly P, Kay S, Small M. Do patients on intranasal fluticasone furoate, mometasone furoate and fluticasone propionate experience similar numbers of symptom-free days and quality of life? A cross-sectional study in three European countries. Poster 380, XXIX Congress of the European Academy of Allergy and Clinical Immunology, London, June 5-9, 2010.
11. Okobu K, Nakashima M, Miyake N, Komatsubara M, Okuda M. Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. Allergy Asthma Proc. 2009;30: 84-94.
12. Garris C, Shah M, D'Souza A, Stanford R. Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms. Clin Drug Investig. 2009;29: 515-26.